Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623000959673
Ethics application status
Approved
Date submitted
28/07/2023
Date registered
4/09/2023
Date last updated
4/04/2024
Date data sharing statement initially provided
4/09/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Lutetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancer
Scientific title
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer
Secondary ID [1] 309695 0
177Lu-RAD204.2023.0001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Non-small Cell Lung Cancer 330762 0
Condition category
Condition code
Cancer 327599 327599 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This study involves the use of investigational compound, 177Lu-RAD204 in patients with PD-L1 positive non-small cell lung cancer. There will be 2 different phases in this study whereby Phase 0 (Imaging period) using 10 mCi of 177Lu-RAD204 and Phase I (treatment period) where 2 different dose levels (30 mCi and 40mCi) of 177Lu-RAD204 will be explored.

The investigational product/IP (177Lu-RAD204) given during Phase 0 will be indicated as 177Lu-RAD204im while the IP given during Phase 1 (treatment period) will be indicated as 177Lu-RAD204tr.

For Phase 0, after undergo screening, if patient is deemed eligible, they will be taking 1 dose of 10mCi of 177Lu-RAD204im and if they tolerate the study drug after 2 weeks, they can roll-over to Phase 1 where patient will receive either 30mCi (dose level 1) or 40mCi (dose level 2) of 177Lu-RAD204tr every 6 weeks with a maximum of 3 doses given.

177Lu-RAD204 will be administered as intravenous (IV) bolus injection under the supervision of the study Investigator or appropriately qualified delegate. Patient medical record will be used to monitor adherence to the intervention.

The continuous safety evaluation will be performed by sponsor, medical monitor, the investigators. A DSMB (Data Safety Monitoring Board) or equivalent committee will be established for the determination of dose escalation and monitoring of dose-limiting toxicity (DLT) for all patients who received 177Lu-RAD204.
Intervention code [1] 326571 0
Diagnosis / Prognosis
Intervention code [2] 326572 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 335456 0
Phase 0

To assess the biodistribution, pharmacokinetics and radiation dosimetry of 177Lu-RAD204im in selected organs and tumour lesions
Timepoint [1] 335456 0
• Time Activity Curves (TACs), describing % of the injected activity vs time will be derived for selected organs and tumours. - Investigational Product (IP) uptake (in % injected activity) over time will be assessed from the multi-timepoint Single Photon Emission Computed Tomography (SPECT CT) images acquired. The images will be analysed using MIM software.

• Absorbed radiation doses of 177Lu-RAD204im in critical organs (kidneys, bone marrow, liver, lungs and bladder) - ICRP phantom-based dosimetry method will be used to calculate internal absorbed radiation doses in the critical organs.

• Half-life of 177Lu-RAD204im in blood at baseline, 1 hr (Day 1), 3 hr (Day 1), 24 hr (Day 2), 48 hr (Day 3), 168 hr (Day 8)

• Time-integrated activity coefficients of 177Lu-RAD204im in organs and tumour lesions - will be derived from the TACs determined per method above using SPECT/CT images.
Primary outcome [2] 335457 0
Phase 1

• To assess the safety and tolerability of 177Lu-RAD204tr
Timepoint [2] 335457 0
• Safety is evaluated with the properties, incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs), abnormal laboratory parameters, vital signs, and electrocardiogram (ECG) results per Common Terminology Criteria for Adverse Event (CTCAE) v5.0- abnormal laboratory parameters & DLTs assessed using blood samples; Vital signs assessed using finger pulse oximeter and digital thermometer;

• Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD204tr injection cycle of treatment
Secondary outcome [1] 424725 0
Phase 0

• To assess the safety and tolerability of a single dose of
177Lu-RAD204im.
Timepoint [1] 424725 0
• Safety is evaluated with the properties, incidence, nature and severity of AEs and SAEs, abnormal laboratory parameters, vital signs, and electrocardiogram (ECG) results per Common Terminology Criteria for Adverse Events (CTCAE) v5.0- abnormal laboratory parameters assessed using blood samples; Vital signs assessed using finger pulse oximeter and digital thermometer.

• Incidence of dose-limiting toxicities (DLTs) in the first 2 weeks following 177Lu-RAD204im injection
Secondary outcome [2] 424726 0
Phase 1

• To assess the preliminary antitumour activity of 177Lu-RAD204tr.
Timepoint [2] 424726 0
• Objective response rates (ORR), Duration of response (DOR) asssessed by RECIST v1.1

• Progression-free survival- Progression free survival is defined as the interval from date of enrolment to the date of first evidence of disease progression or death from any cause, whichever occurs first.
Secondary outcome [3] 424727 0
Phase 1

• To assess the biodistribution, pharmacokinetic and radiation dosimetry of 177Lu-RAD204tr
Timepoint [3] 424727 0
• Time Activity Curves (TACs), describing % of the injected activity vs time will be derived for selected organs and tumours. - Investigational Product (IP) uptake (in % injected activity) over time will be assessed from the multi-timepoint Single Photon Emission Computed Tomography (SPECT CT) images acquired. The images will be analysed using MIM software.

• Absorbed radiation doses of 177Lu-RAD204tr in critical organs (kidneys, bone marrow, liver, lungs and bladder) - ICRP phantom-based dosimetry method will be used to calculate internal absorbed radiation doses in the critical organs.

• Half-life of 177Lu-RAD204tr in blood at baseline, 1 hr (Day 1), 3 hr (Day 1), 24 hr (Day 2), 48 hr (Day 3), 168 hr (Day 8)

• Time-integrated activity coefficients of 177Lu-RAD204tr in organs and tumour lesions - will be derived from the TACs determined per method above using SPECT/CT images. .

Eligibility
Key inclusion criteria
Inclusion criteria
To be eligible for study, a participant must meet all of the following inclusion criteria:

1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
2. Adult participants greater than or equal to 18 years of age.
3. Participants with a documented history of histopathological confirmed metastatic NSCLC that is unresectable, progressive and for which standard treatment measures are no longer effective.
4. Participants with a documented history of PD-L1 positive NSCLC
- Any number of prior treatment lines are allowed in this study, however at least one of the treatment line(s) must include an anti-PD(L)-1 antibody.
- Participants with any documented PD-L1 positivity by immunohistochemistry (IHC) without prior treatment with anti-PD(L)-1 antibody may be allowed on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
6. Participants must have a life expectancy of >4 months in the opinion of the Investigator.
7. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (ß-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female subjects will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Female subjects < 50 years old who meet the criteria for post-menopausal status without previous surgical sterilisation should be considered for further investigation with luteinising hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status.
8. WOCBP must agree to use a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later.
9. Male subjects who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. All male subjects must agree to not donate sperm during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 4 months after the last dose of Lu-RAD204tr, whichever occurs later.
10. Subjects with previously treated brain metastases are eligible to participate if:
- they are clinically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-RAD204; and any neurologic symptoms returned to baseline.
- Note: Subjects with a history of leptomeningeal disease may not participate even if stable clinically.
11. For Phase I: Participants must have positive lesion(s) by 177Lu-RAD204im Single Photon Emission Computer Tomography (SPECT/CT) as described in Image Review Manual. Estimated total radiation dose to healthy organs derived from phase 0 dosimetry must not exceed dose constraints according to the American Association of Physicists in Medicine Quantitative Analysis of Normal Tissue Effect in the Clinic (QUANTEC) and International Commission on Radiological Protection (ICRP), in discussion with study Sponsor.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria
A participant who meets any of the following exclusion criteria must be excluded from study:

1. History of prior organ transplant.
2. Any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer. Patients with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
3. Have any medical condition that would, in the Investigator’s judgment, prevent the participant’s full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time point imaging procedures, etc.
4. Residual toxicity > Grade 1 from prior anti-cancer therapy (except alopecia). Participants with > Grade 1 toxicity from prior anti-cancer therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
5. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to protein therapeutics, 177Lu-RAD204 or any of its excipients.
6. Inadequate organ functions as reflected in laboratory parameters:
• Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x upper limit of normal (ULN)
• Platelet count of < 75 x 10^9/L
• Absolute neutrophil count (ANC) < 1.0 x 10^9/L
• Haemoglobin < 9 g/dL
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN, or > 5 x ULN for patients with known liver metastases
• Total bilirubin > 1.5 x ULN, except for patients with documented Gilbert’s syndrome who are eligible if total bilirubin is less than or equal to 3 x ULN
• For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) less than or equal to 1.5 or prothrombin time (PT) less than or equal to 1.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) less than or equal to 1.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR <3.5. Among participants receiving
other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
7. Patients requiring blood product transfusion within 4 weeks of first dose of 177Lu-RAD204tr are not eligible to participate.
8. Clinically significant cardiovascular disease including but not limited to:
• Unstable angina or acute myocardial infarction within 6 months prior to screening
• Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (New York Heart Association (NYHA) grade greater than or equal to 2)
• Uncontrolled arterial hypertension or unstable clinically significant arrhythmia
• Known left ventricular ejection fraction (LVEF) < 50%
• QTcF > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome.
9. Participation in any other investigational trial at the time of informed consent signature.
10. Pregnant or lactating women.

The following exclusion criteria applies to participants in Phase I:

11. Major surgery within 4 weeks prior to first dose of 177Lu-RAD204tr. Exceptions may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
12. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD204tr. Focal palliative radiotherapy given within 28 days prior to the first dose of 177Lu-RAD204tr may be approved on a case-by-case basis in discussion with the Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome. For participants who received radiotherapy more than 28 days prior to the first dose of 177Lu-RAD204tr, efforts should be made to calculate the prior radiation absorbed dose to each critical organ such as the kidneys, liver, lungs, and bone marrow. The absorbed dose limits for critical
organs should not exceed the cumulative absorbed dose from the prior radiopharmaceutical and/or external beam radiation therapy (EBRT) treatment(s) and the planned course of treatment in this study. Participants who would have cumulative absorbed dose to critical organs exceeded will not be enrolled in the study.
13. Has had or is scheduled to have major surgery < 28 days prior to the first dose of 177Lu-RAD204tr. Elective surgical procedures not considered to put participants at higher risk of AEs may be allowed on a case-by-case basis in discussion with the Sponsor.
14. Positive status for human immunodeficiency virus (HIV).
15. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.
16. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.
17. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Eligible patient will receive single dose of 177Lu-RAD204im in Phase 0 and if no safety concern, patient will roll-over to Phase 1 to receive 177Lu-RAD204tr (one of the 2 treatment dose levels).
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
15/04/2024
Actual
Date of last participant enrolment
Anticipated
31/03/2025
Actual
Date of last data collection
Anticipated
3/07/2025
Actual
Sample size
Target
23
Accrual to date
0
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 25244 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [2] 26183 0
Hollywood Private Hospital - Nedlands
Recruitment hospital [3] 26184 0
Wollongong Hospital - Wollongong
Recruitment postcode(s) [1] 42056 0
2500 - Wollongong
Recruitment postcode(s) [2] 40917 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 42055 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 313889 0
Commercial sector/Industry
Name [1] 313889 0
Radiopharm Theranostics Ltd
Country [1] 313889 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Radiopharm Theranostics Ltd
Address
Suite 1, Level 3, 62 Lygon Street
Carlton South, VIC 3053
Country
Australia
Secondary sponsor category [1] 315736 0
Commercial sector/Industry
Name [1] 315736 0
GenesisCare Clinical CRO Pty Ltd
Address [1] 315736 0
Buildings 7C & D, Level 1. The Mill, 41-43 Bourke Road
Alexandria NSW 2015
Country [1] 315736 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 313036 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 313036 0
Level 7, Translational Research Institute Building
Princess Alexandra Hospital
Ipswich Road, Woolloongabba Qld 4102
Ethics committee country [1] 313036 0
Australia
Date submitted for ethics approval [1] 313036 0
12/07/2023
Approval date [1] 313036 0
06/10/2023
Ethics approval number [1] 313036 0
Ethics committee name [2] 314699 0
Bellberry Human Research Ethics Committee
Ethics committee address [2] 314699 0
123 Glen Osmond Road
Eastwood South Australia 5063
Ethics committee country [2] 314699 0
Australia
Date submitted for ethics approval [2] 314699 0
06/11/2023
Approval date [2] 314699 0
22/12/2023
Ethics approval number [2] 314699 0

Summary
Brief summary
This study is evaluating the safety and properties of 177Lu-RAD204, a PD-L1 antibody joined to a radioactive lutetium isotope.

Who is it for?
You may be eligible for this study if you are an adult patient with confirmed metastatic PD-L1 positive non-small cell lung cancer (NSCLC) that is unresectable, progressive and for which standard treatment measures are no longer effective.

Study details
Participants will undergo a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and receiving a single injection of 177Lu-RAD204. If they are able to tolerate this in the following 2 week period, they will then proceed to a Phase I (Treatment) Period where they will be assigned a dose of 177Lu-RAD204 delivered every 6 weeks with a maximum of 3 doses given. Blood sampling and imaging studies will be performed to determine how the participant is responding to 177Lu-RAD204.

Findings from this study will help determine a recommended dose of 177Lu-RAD204 for future exploration
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 126762 0
A/Prof Joe Cardaci
Address 126762 0
Diagnostic Nuclear Imaging, Hollywood Private Hospital, 101 Monash Avenue Nedlands 6009 WA
Country 126762 0
Australia
Phone 126762 0
+61412556901
Fax 126762 0
Email 126762 0
jcardaci@dni.com.au
Contact person for public queries
Name 126763 0
Prof Sin Yee Yeoh
Address 126763 0
GenesisCare Clinical CRO
Building 7, The Mill, 41-43 Bourke Road
Alexandria NSW 2015
Country 126763 0
Australia
Phone 126763 0
+61 481875123
Fax 126763 0
Email 126763 0
sinyee.yeoh@genesiscare.com
Contact person for scientific queries
Name 126764 0
Dr Sherin Al-Safadi
Address 126764 0
Radiopharm Theranostics Pty.Suite 1, Level 3, 62 Lygon StreetCarlton South, VIC 3053
Country 126764 0
Australia
Phone 126764 0
+61 03 98245254
Fax 126764 0
Email 126764 0
sa@radiopharmtheranostics.com

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
No individual participant data will be publicly available. Data will be anonymised and analysed as a cohort.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.